BroadOak Logo

Cenetron Sells To Versiti

BroadOak Partners advised Cenetron Diagnostics (“Cenetron”) on the sale of the company to Versiti. Cenetron provides central laboratory services to support global clinical trials for biopharmaceutical, diagnostic, and contract research organizations.

The full press release is below.

Versiti Acquires Texas-based Cenetron Central Laboratories and Salus IRB to Advance Clinical Trial Capabilities

Milwaukee, Wis., – July 12, 2019 – Versiti, a national leader in blood health innovation, today announced the acquisition of Texas-based Cenetron Central Laboratories, and its subsidiary, Salus IRB, offering both organizations the opportunity to expand clinical trial services and expertise.

“By joining forces with an industry leader such as Cenetron, we gain the strength of an organization that specializes in pre-analytical activities that are critical to the success of clinical trials,” said Versiti President and CEO Chris Miskel. “Clinical trials are critical to medical advances that translate to patient care. Together with Versiti’s extensive clinical trial expertise – we will better serve our existing customers, and offer expanded service to future customers.”

Cenetron will provide Versiti’s diagnostic laboratories with a spectrum of clinical trial solutions from project initiation, kit development and sample logistics, specialized testing, data management, and project management. Salus IRB, an AAHRPP-accredited, Independent Review Board, provides in-depth regulatory expertise to support the development of ethical and quality research designs for the biopharmaceutical and medical device industries.

The acquisition will not impact Cenetron’s 40 employees, and the laboratory will maintain its name and current location in Austin. Versiti, headquartered in Milwaukee, has 2,000 employees at its locations in Illinois, Indiana, Michigan, Ohio and Wisconsin.

“Versiti and Cenetron are dedicated to a common mission of advancing medical science, and patient care, through clinical trials,” said Cenetron President Dwight DuBois, M.D. “Versiti has a long history of impeccable customer service, combined with the highest standards of quality and in-depth scientific expertise. The entire Cenetron organization is both excited and proud to be aligned with an organization with Versiti’s sterling reputation.”

Dr. DuBois will remain at Cenetron as the laboratory’s medical director.

Original Press Release